Selecta is developing tSVP™ and t²SVP™ products for a broad range of therapeutic and prophylactic applications, including addiction, cancer, autoimmune disease, and infectious diseases.  Medical indications include: tSVP™ for smoking cessation and relapse prevention (SEL-068); tSVP™ for mlaria; tSVP™ for universal influenza, and t²SVP™ tolerogenic vaccine for treatment of type 1 diabetes.

Selecta is rapidly developing its lead programs and initiated a Phase 1 human clinical trial for its lead product candidate, SEL-068 in 2011. The Phase 1 clinical study of SEL-068 is a double-blind, placebo-controlled, ascending dose study in healthy, non-smoking and smoking volunteers. In addition to safety, this study evaluates the vaccine's potency through the measurement of concentrations of nicotine-specific antibodies. Results from this Phase 1 study are expected to be reported in the first half of 2012.